𝗖𝗘𝗕𝗜𝗢𝗧𝗘𝗫 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝗮 𝗸𝗲𝘆 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲: 𝘁𝗵𝗲 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝗶𝗻-𝗵𝗼𝘂𝘀𝗲 𝗚𝗠𝗣-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗵𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗖𝗘𝗕-𝟬𝟭, advancing local control of pancreatic cancer and abdominal tumors in children.

We are proud to announce a major step forward in our strategic plan: the start-up of our own 𝗚𝗠𝗣-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 facilities, located within the plant of our key partner, PRASFARMA. This strengthens our capacity to ramp up 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗖𝗘𝗕-𝟬𝟭 to supply 𝗼𝘂𝗿 𝗼𝗻𝗴𝗼𝗶𝗻𝗴 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗮𝗻𝗱 𝗽𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗮𝗯𝗱𝗼𝗺𝗶𝗻𝗮𝗹 𝘁𝘂𝗺𝗼𝗿𝘀, and to prepare for future market launch.

W𝗶𝘁𝗵 𝗼𝘂𝗿 𝘂𝗻𝗶𝗾𝘂𝗲, 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗽𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆, we gain greater control over production processes while 𝗲𝗻𝘀𝘂𝗿𝗶𝗻𝗴 𝗳𝘂𝗹𝗹 𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 𝘄𝗶𝘁𝗵 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀.

This milestone marks a key step in our long-term strategy to position 𝗖𝗘𝗕-𝟬𝟭 𝗮𝘀 𝗮 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗮 𝗺𝗮𝗷𝗼𝗿 𝘂𝗻𝗺𝗲𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗻𝗲𝗲𝗱 𝗶𝗻 𝗹𝗼𝗰𝗮𝗹 𝗽𝗼𝘀𝘁-𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 — aiming to significantly improve patient survival.

W𝗲 𝗿𝗲𝗺𝗮𝗶𝗻 𝗰𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗖𝗘𝗕-𝟬𝟭 and exploring new collaborations to bring innovation to oncology.

.